


PHARMACEUTICAL 2017



Clovis Oncology Inc. Rank 236 of 292





PHARMACEUTICAL 2017



Clovis Oncology Inc. Rank 236 of 292

The relative strengths and weaknesses of Clovis Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Clovis Oncology Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Clovis Oncology Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is -97%, being 100% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	279,410
Cost of Goods Sold	0
Intangible Assets	78,239
Liabilities, Current	65,597
Liabilities, Non-Current	0
Other Assets	2,468
Other Compr. Net Income	-120
Other Expenses	47,617
Other Liabilities	302,594
Other Net Income	-8,438
Other Revenues	78
Property and Equipment	4,440
Research and Development	252,429
Selling, General and Administrative Expense	40,731

Output Variable	Value in 1000 USD
Assets	364,557
Liabilities	368,191
Expenses	340,777
Revenues	78
Stockholders Equity	-3,634
Net Income	-349,137
Comprehensive Net Income	-349,197
Economic Capital Ratio	-97%

